(Yicai Global) April 16 -- Shares of Maccura Biotechnology jumped to a four-year high after the Chinese firm said that the US Food and Drug Administration has approved its Covid-19 test kit for emergency use in the States.

Maccura's shares [SHE: 300463] climbed by the daily limit of 10 percent to CNY35.22 (USD4.80) today, the highest since December 2015.

The company's nucleic acid test can detect the three characteristic genes of the coronavirus, which makes it more reliable, the Chengdu-based firm said in a statement today. The diagnostic tool can comb through 96 samples in two hours.

The test kit has already gotten the green light from Chinese authorities, as well as obtained the European Union's CE marking, the company added.

Editor: Emmi Laine